CLEC4M and COVID-19: Anti–L-SIGN, mannan, or L-SIGN/Fc recombinant protein dose-dependently blocked L-SIGN–mediated CoV-2–type infection but not control VSVG-type infection, indicating specific inhibition of L-SIGN–mediated CoV-2 infection.